Healthcare provider profile · identity verified

Mark Ayad Matta, DO

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · NEW CASTLE, PA · NPI 1245424084

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Mark Ayad Matta, DO received $258,179.01 in general payments during 2025 across 464 reported records.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 27.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 23 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Austedo Xr, Auvelity, Azstarys, Caplyta, Lybalvi, Rexulti, Trintellix, Vraylar.

ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Vraylar by this doctor in 2024.

Alkermes, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYBALVI as an associated drug or biological on 93784 records involving 20135 distinct recipient NPIs. Public Medicare Part D data also shows 56 claims for Lybalvi by this doctor in 2024.

Axsome Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Auvelity as an associated drug or biological on 116023 records involving 35298 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Auvelity by this doctor in 2024.

Corium, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Azstarys as an associated drug or biological on 54930 records involving 15827 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Azstarys by this doctor in 2024.

ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CAPLYTA as an associated drug or biological on 211855 records involving 46143 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Caplyta by this doctor in 2024.

Janssen Pharmaceuticals, Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Caplyta as an associated drug or biological on 11 records involving 9 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Caplyta by this doctor in 2024.

Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Nuedexta by this doctor in 2024.

Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Rexulti by this doctor in 2024.

Takeda Pharmaceuticals U.S.A., Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRINTELLIX as an associated drug or biological on 37075 records involving 14402 distinct recipient NPIs. Public Medicare Part D data also shows 132 claims for Trintellix by this doctor in 2024.

Teva Pharmaceuticals USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AUSTEDO XR as an associated drug or biological on 86263 records involving 23643 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Austedo Xr by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$258,179.01

464 reported records · 18 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	Unresolved — no canonical attribution shown	$70,798.90	27.4%	67	2025
Vanda Pharmaceuticals Inc.	Unresolved — no canonical attribution shown	$70,599.95	27.4%	101	2025
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$34,544.37	13.4%	48	2025
Teva Pharmaceuticals USA, Inc.	Unresolved — no canonical attribution shown	$28,008.03	10.8%	48	2025
Otsuka America Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$26,363.48	10.2%	47	2025
Alkermes, Inc.	Unresolved — no canonical attribution shown	$21,234.75	8.2%	53	2025
ABBVIE INC.	Unresolved — no canonical attribution shown	$5,311.66	2.1%	42	2025
Neurocrine BioSciences, Inc.	Unresolved — no canonical attribution shown	$470.27	0.2%	13	2025
Janssen Pharmaceuticals, Inc	Unresolved — no canonical attribution shown	$226.92	0.1%	12	2025
Corium, LLC	Unresolved — no canonical attribution shown	$114.46	0.0%	7	2025
Axsome Therapeutics, Inc.	Unresolved — no canonical attribution shown	$100.33	0.0%	4	2025
Supernus Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$79.07	0.0%	4	2025
Lundbeck LLC	Unresolved — no canonical attribution shown	$77.03	0.0%	4	2025
Takeda Pharmaceuticals U.S.A., Inc.	Unresolved — no canonical attribution shown	$65.57	0.0%	4	2025
Sage Therapeutics, LLC	Unresolved — no canonical attribution shown	$64.34	0.0%	3	2025
Collegium Pharmaceutical, Inc.	Unresolved — no canonical attribution shown	$55.41	0.0%	3	2025
Almatica Pharma LLC	Unresolved — no canonical attribution shown	$46.69	0.0%	3	2025
Otsuka Pharmaceutical Development & Commercialization, Inc.	Unresolved — no canonical attribution shown	$17.78	0.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program	$188,007.00	73
Travel and Lodging	$47,383.77	102
Consulting Fee	$12,386.00	5
Food and Beverage	$10,300.75	283
Education	$101.49	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
CAPLYTA Normalized: caplyta	Drug	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	$70,798.90	67	2025
Source payment records 2025-01-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $32.74 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.99 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,320.00 · Open Payments source 2025-03-04 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,192.78 · Open Payments source 2025-04-16 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.14 · Open Payments source 2025-06-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.29 · Open Payments source 2025-06-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $14.63 · Open Payments source 2025-06-25 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2.12 · Open Payments source 2025-06-26 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $29.28 · Open Payments source 2025-07-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,191.68 · Open Payments source 2025-07-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $123.72 · Open Payments source 2025-07-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-07-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.28 · Open Payments source 2025-08-19 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $17.34 · Open Payments source 2025-09-24 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $18.84 · Open Payments source 2025-10-07 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.45 · Open Payments source 2025-10-09 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $22.12 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $284.98 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.70 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $235.00 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $306.75 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $144.19 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $33.76 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $56.87 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $49.33 · Open Payments source 2025-10-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $34.57 · Open Payments source 2025-10-14 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.54 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.88 · Open Payments source 2025-10-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $695.71 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $31.90 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-10-21 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $604.85 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,427.48 · Open Payments source 2025-10-22 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $114.47 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $2,775.00 · Open Payments source 2025-10-23 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $26.54 · Open Payments source 2025-10-27 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $129.71 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $27.30 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $937.59 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $124.74 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $100.00 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4.63 · Open Payments source 2025-10-29 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $65.80 · Open Payments source 2025-10-30 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $654.51 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-11-05 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $115.50 · Open Payments source 2025-11-06 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $48.56 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-11-11 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $10.71 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $130.00 · Open Payments source 2025-11-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $904.58 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $122.67 · Open Payments source 2025-11-13 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $1,186.28 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $21.19 · Open Payments source 2025-11-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $28.33 · Open Payments source 2025-11-18 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $744.10 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-11-20 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $4,440.00 · Open Payments source 2025-12-12 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $3,885.00 · Open Payments source 2025-12-17 · ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) · $15.28 · Open Payments source
FANAPT Normalized: fanapt	Drug	Vanda Pharmaceuticals Inc.	$70,599.95	101	2025
Source payment records 2025-01-06 · Vanda Pharmaceuticals Inc. · $11.37 · Open Payments source 2025-01-06 · Vanda Pharmaceuticals Inc. · $2.54 · Open Payments source 2025-01-17 · Vanda Pharmaceuticals Inc. · $19.31 · Open Payments source 2025-01-28 · Vanda Pharmaceuticals Inc. · $31.66 · Open Payments source 2025-01-28 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-01-28 · Vanda Pharmaceuticals Inc. · $1,088.28 · Open Payments source 2025-02-26 · Vanda Pharmaceuticals Inc. · $113.03 · Open Payments source 2025-02-26 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-02-26 · Vanda Pharmaceuticals Inc. · $88.00 · Open Payments source 2025-02-27 · Vanda Pharmaceuticals Inc. · $124.98 · Open Payments source 2025-02-27 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-02-27 · Vanda Pharmaceuticals Inc. · $1,310.70 · Open Payments source 2025-03-03 · Vanda Pharmaceuticals Inc. · $20.22 · Open Payments source 2025-03-03 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-03-03 · Vanda Pharmaceuticals Inc. · $56.43 · Open Payments source 2025-03-26 · Vanda Pharmaceuticals Inc. · $19.84 · Open Payments source 2025-04-07 · Vanda Pharmaceuticals Inc. · $33.19 · Open Payments source 2025-04-07 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-04-07 · Vanda Pharmaceuticals Inc. · $1,219.31 · Open Payments source 2025-04-14 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-04-14 · Vanda Pharmaceuticals Inc. · $65.80 · Open Payments source 2025-04-22 · Vanda Pharmaceuticals Inc. · $15.98 · Open Payments source 2025-04-22 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-04-22 · Vanda Pharmaceuticals Inc. · $35.00 · Open Payments source 2025-04-24 · Vanda Pharmaceuticals Inc. · $15.13 · Open Payments source 2025-05-01 · Vanda Pharmaceuticals Inc. · $22.91 · Open Payments source 2025-05-12 · Vanda Pharmaceuticals Inc. · $40.00 · Open Payments source 2025-05-21 · Vanda Pharmaceuticals Inc. · $123.97 · Open Payments source 2025-05-21 · Vanda Pharmaceuticals Inc. · $2,475.00 · Open Payments source 2025-05-21 · Vanda Pharmaceuticals Inc. · $1,715.16 · Open Payments source 2025-05-23 · Vanda Pharmaceuticals Inc. · $5.93 · Open Payments source 2025-05-28 · Vanda Pharmaceuticals Inc. · $124.99 · Open Payments source 2025-05-28 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-05-28 · Vanda Pharmaceuticals Inc. · $997.88 · Open Payments source 2025-06-12 · Vanda Pharmaceuticals Inc. · $1,670.00 · Open Payments source 2025-06-12 · Vanda Pharmaceuticals Inc. · $57.06 · Open Payments source 2025-06-25 · Vanda Pharmaceuticals Inc. · $125.00 · Open Payments source 2025-06-25 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-06-25 · Vanda Pharmaceuticals Inc. · $1,391.83 · Open Payments source 2025-07-14 · Vanda Pharmaceuticals Inc. · $14.38 · Open Payments source 2025-07-16 · Vanda Pharmaceuticals Inc. · $37.00 · Open Payments source 2025-07-29 · Vanda Pharmaceuticals Inc. · $24.05 · Open Payments source 2025-08-04 · Vanda Pharmaceuticals Inc. · $29.73 · Open Payments source 2025-08-04 · Vanda Pharmaceuticals Inc. · $1,320.00 · Open Payments source 2025-08-04 · Vanda Pharmaceuticals Inc. · $17.50 · Open Payments source 2025-08-04 · Vanda Pharmaceuticals Inc. · $34.00 · Open Payments source 2025-08-04 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-08-04 · Vanda Pharmaceuticals Inc. · $28.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $175.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $691.92 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $4,455.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $325.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $35.00 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $38.13 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $178.12 · Open Payments source 2025-08-15 · Vanda Pharmaceuticals Inc. · $219.22 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $69.90 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $29.52 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $3.99 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $32.61 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $49.55 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $2.66 · Open Payments source 2025-08-16 · Vanda Pharmaceuticals Inc. · $79.73 · Open Payments source 2025-08-20 · Vanda Pharmaceuticals Inc. · $31.61 · Open Payments source 2025-08-20 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-08-20 · Vanda Pharmaceuticals Inc. · $1,120.08 · Open Payments source 2025-09-16 · Vanda Pharmaceuticals Inc. · $125.00 · Open Payments source 2025-09-16 · Vanda Pharmaceuticals Inc. · $1,980.00 · Open Payments source 2025-09-16 · Vanda Pharmaceuticals Inc. · $2,303.90 · Open Payments source 2025-09-16 · Vanda Pharmaceuticals Inc. · $1,126.27 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $125.00 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $69.63 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $22.94 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $2,145.00 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $306.25 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $34.80 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $20.40 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $124.46 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $19.31 · Open Payments source 2025-09-18 · Vanda Pharmaceuticals Inc. · $32.57 · Open Payments source 2025-09-22 · Vanda Pharmaceuticals Inc. · $32.05 · Open Payments source 2025-09-22 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-09-22 · Vanda Pharmaceuticals Inc. · $789.96 · Open Payments source 2025-09-23 · Vanda Pharmaceuticals Inc. · $25.33 · Open Payments source 2025-09-23 · Vanda Pharmaceuticals Inc. · $1,320.00 · Open Payments source 2025-09-23 · Vanda Pharmaceuticals Inc. · $39.80 · Open Payments source 2025-09-23 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-09-23 · Vanda Pharmaceuticals Inc. · $1,713.56 · Open Payments source 2025-09-25 · Vanda Pharmaceuticals Inc. · $7.32 · Open Payments source 2025-09-25 · Vanda Pharmaceuticals Inc. · $566.50 · Open Payments source 2025-10-01 · Vanda Pharmaceuticals Inc. · $23.41 · Open Payments source 2025-10-01 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-10-01 · Vanda Pharmaceuticals Inc. · $854.81 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $81.85 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $2,475.00 · Open Payments source 2025-12-03 · Vanda Pharmaceuticals Inc. · $2,718.63 · Open Payments source 2025-12-22 · Vanda Pharmaceuticals Inc. · $20.47 · Open Payments source 2025-12-22 · Vanda Pharmaceuticals Inc. · $1,650.00 · Open Payments source 2025-12-22 · Vanda Pharmaceuticals Inc. · $63.53 · Open Payments source
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$32,328.37	47	2025
Source payment records 2025-01-06 · E.R. Squibb & Sons, L.L.C. · $8.63 · Open Payments source 2025-01-30 · E.R. Squibb & Sons, L.L.C. · $19.88 · Open Payments source 2025-03-13 · E.R. Squibb & Sons, L.L.C. · $110.44 · Open Payments source 2025-03-27 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-04-09 · E.R. Squibb & Sons, L.L.C. · $120.47 · Open Payments source 2025-04-09 · E.R. Squibb & Sons, L.L.C. · $761.28 · Open Payments source 2025-04-15 · E.R. Squibb & Sons, L.L.C. · $9.26 · Open Payments source 2025-04-15 · E.R. Squibb & Sons, L.L.C. · $42.00 · Open Payments source 2025-04-30 · E.R. Squibb & Sons, L.L.C. · $124.20 · Open Payments source 2025-04-30 · E.R. Squibb & Sons, L.L.C. · $870.47 · Open Payments source 2025-05-01 · E.R. Squibb & Sons, L.L.C. · $3,323.00 · Open Payments source 2025-05-12 · E.R. Squibb & Sons, L.L.C. · $3,876.00 · Open Payments source 2025-05-22 · E.R. Squibb & Sons, L.L.C. · $96.31 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $28.94 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $113.40 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $160.37 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $284.90 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $807.68 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $178.71 · Open Payments source 2025-06-05 · E.R. Squibb & Sons, L.L.C. · $980.32 · Open Payments source 2025-06-10 · E.R. Squibb & Sons, L.L.C. · $2,769.00 · Open Payments source 2025-06-13 · E.R. Squibb & Sons, L.L.C. · $7.68 · Open Payments source 2025-06-13 · E.R. Squibb & Sons, L.L.C. · $42.00 · Open Payments source 2025-06-20 · E.R. Squibb & Sons, L.L.C. · $4,430.00 · Open Payments source 2025-06-20 · E.R. Squibb & Sons, L.L.C. · $1,994.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $56.03 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $45.00 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $66.22 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $85.79 · Open Payments source 2025-07-07 · E.R. Squibb & Sons, L.L.C. · $81.26 · Open Payments source 2025-07-17 · E.R. Squibb & Sons, L.L.C. · $14.57 · Open Payments source 2025-08-28 · E.R. Squibb & Sons, L.L.C. · $107.95 · Open Payments source 2025-08-28 · E.R. Squibb & Sons, L.L.C. · $1,034.32 · Open Payments source 2025-08-28 · E.R. Squibb & Sons, L.L.C. · $675.34 · Open Payments source 2025-09-10 · E.R. Squibb & Sons, L.L.C. · $3,655.00 · Open Payments source 2025-09-10 · E.R. Squibb & Sons, L.L.C. · $1,661.00 · Open Payments source 2025-09-29 · E.R. Squibb & Sons, L.L.C. · $6.63 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $134.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $49.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $64.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $326.09 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $29.99 · Open Payments source 2025-10-09 · E.R. Squibb & Sons, L.L.C. · $51.73 · Open Payments source 2025-11-12 · E.R. Squibb & Sons, L.L.C. · $170.43 · Open Payments source 2025-12-16 · E.R. Squibb & Sons, L.L.C. · $23.13 · Open Payments source
REXULTI Normalized: rexulti	Drug	Lundbeck LLC, Otsuka America Pharmaceutical, Inc.	$26,419.73	50	2025
Source payment records 2025-01-07 · Otsuka America Pharmaceutical, Inc. · $23.87 · Open Payments source 2025-01-25 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-02-04 · Otsuka America Pharmaceutical, Inc. · $22.31 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $11.07 · Open Payments source 2025-02-27 · Otsuka America Pharmaceutical, Inc. · $4.89 · Open Payments source 2025-03-05 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-03-08 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-03-26 · Otsuka America Pharmaceutical, Inc. · $124.88 · Open Payments source 2025-03-28 · Otsuka America Pharmaceutical, Inc. · $840.12 · Open Payments source 2025-04-02 · Otsuka America Pharmaceutical, Inc. · $3,078.00 · Open Payments source 2025-04-07 · Otsuka America Pharmaceutical, Inc. · $22.16 · Open Payments source 2025-04-16 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-04-21 · Otsuka America Pharmaceutical, Inc. · $7.99 · Open Payments source 2025-04-21 · Lundbeck LLC · $22.94 · Open Payments source 2025-04-28 · Otsuka America Pharmaceutical, Inc. · $5.81 · Open Payments source 2025-04-28 · Otsuka America Pharmaceutical, Inc. · $21.25 · Open Payments source 2025-05-01 · Lundbeck LLC · $15.22 · Open Payments source 2025-05-09 · Otsuka America Pharmaceutical, Inc. · $351.00 · Open Payments source 2025-05-28 · Otsuka America Pharmaceutical, Inc. · $28.74 · Open Payments source 2025-05-29 · Otsuka America Pharmaceutical, Inc. · $126.58 · Open Payments source 2025-05-29 · Otsuka America Pharmaceutical, Inc. · $296.37 · Open Payments source 2025-05-31 · Otsuka America Pharmaceutical, Inc. · $169.77 · Open Payments source 2025-06-04 · Otsuka America Pharmaceutical, Inc. · $3,564.00 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $49.77 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $64.77 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $72.00 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $9.26 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $25.00 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $25.00 · Open Payments source 2025-06-11 · Otsuka America Pharmaceutical, Inc. · $66.22 · Open Payments source 2025-07-02 · Otsuka America Pharmaceutical, Inc. · $24.00 · Open Payments source 2025-07-24 · Lundbeck LLC · $17.34 · Open Payments source 2025-07-28 · Otsuka America Pharmaceutical, Inc. · $20.49 · Open Payments source 2025-09-05 · Otsuka America Pharmaceutical, Inc. · $30.25 · Open Payments source 2025-09-05 · Otsuka America Pharmaceutical, Inc. · $1.82 · Open Payments source 2025-09-05 · Otsuka America Pharmaceutical, Inc. · $6.57 · Open Payments source 2025-09-30 · Otsuka America Pharmaceutical, Inc. · $22.36 · Open Payments source 2025-10-03 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-10-08 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-10-08 · Lundbeck LLC · $21.53 · Open Payments source 2025-10-16 · Otsuka America Pharmaceutical, Inc. · $16.53 · Open Payments source 2025-10-16 · Otsuka America Pharmaceutical, Inc. · $6.79 · Open Payments source 2025-10-30 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-11-05 · Otsuka America Pharmaceutical, Inc. · $295.26 · Open Payments source 2025-11-06 · Otsuka America Pharmaceutical, Inc. · $701.36 · Open Payments source 2025-11-20 · Otsuka America Pharmaceutical, Inc. · $1.14 · Open Payments source 2025-11-20 · Otsuka America Pharmaceutical, Inc. · $5.30 · Open Payments source 2025-11-26 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source 2025-12-19 · Otsuka America Pharmaceutical, Inc. · $1,620.00 · Open Payments source
LYBALVI Normalized: lybalvi	Drug	Alkermes, Inc.	$21,149.81	47	2025
Source payment records 2025-01-02 · Alkermes, Inc. · $2.97 · Open Payments source 2025-01-02 · Alkermes, Inc. · $13.51 · Open Payments source 2025-02-14 · Alkermes, Inc. · $82.14 · Open Payments source 2025-02-19 · Alkermes, Inc. · $114.30 · Open Payments source 2025-02-20 · Alkermes, Inc. · $118.16 · Open Payments source 2025-02-27 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-03-05 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-03-06 · Alkermes, Inc. · $6.10 · Open Payments source 2025-03-06 · Alkermes, Inc. · $58.10 · Open Payments source 2025-03-06 · Alkermes, Inc. · $43.40 · Open Payments source 2025-03-06 · Alkermes, Inc. · $9.26 · Open Payments source 2025-04-04 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-04 · Alkermes, Inc. · $125.00 · Open Payments source 2025-04-04 · Alkermes, Inc. · $24.95 · Open Payments source 2025-04-05 · Alkermes, Inc. · $61.69 · Open Payments source 2025-04-05 · Alkermes, Inc. · $266.96 · Open Payments source 2025-04-05 · Alkermes, Inc. · $238.26 · Open Payments source 2025-04-05 · Alkermes, Inc. · $2.88 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.27 · Open Payments source 2025-04-05 · Alkermes, Inc. · $60.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $48.66 · Open Payments source 2025-04-05 · Alkermes, Inc. · $75.00 · Open Payments source 2025-04-05 · Alkermes, Inc. · $23.00 · Open Payments source 2025-04-24 · Alkermes, Inc. · $4,470.00 · Open Payments source 2025-05-02 · Alkermes, Inc. · $66.22 · Open Payments source 2025-05-02 · Alkermes, Inc. · $9.26 · Open Payments source 2025-05-02 · Alkermes, Inc. · $72.00 · Open Payments source 2025-05-02 · Alkermes, Inc. · $23.47 · Open Payments source 2025-05-07 · Alkermes, Inc. · $17.22 · Open Payments source 2025-05-22 · Alkermes, Inc. · $32.20 · Open Payments source 2025-05-28 · Alkermes, Inc. · $15.08 · Open Payments source 2025-06-16 · Alkermes, Inc. · $22.06 · Open Payments source 2025-07-03 · Alkermes, Inc. · $26.00 · Open Payments source 2025-08-13 · Alkermes, Inc. · $800.00 · Open Payments source 2025-09-04 · Alkermes, Inc. · $19.79 · Open Payments source 2025-09-10 · Alkermes, Inc. · $101.99 · Open Payments source 2025-09-16 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-09-26 · Alkermes, Inc. · $42.70 · Open Payments source 2025-09-26 · Alkermes, Inc. · $6.10 · Open Payments source 2025-10-02 · Alkermes, Inc. · $129.78 · Open Payments source 2025-10-15 · Alkermes, Inc. · $937.59 · Open Payments source 2025-10-15 · Alkermes, Inc. · $125.00 · Open Payments source 2025-10-16 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-10-23 · Alkermes, Inc. · $2,550.00 · Open Payments source 2025-11-05 · Alkermes, Inc. · $18.61 · Open Payments source 2025-12-03 · Alkermes, Inc. · $17.59 · Open Payments source 2025-12-18 · Alkermes, Inc. · $26.27 · Open Payments source
AUSTEDO XR Normalized: austedo xr	Drug	Teva Pharmaceuticals USA, Inc.	$15,253.35	29	2025
Source payment records 2025-01-13 · Teva Pharmaceuticals USA, Inc. · $836.55 · Open Payments source 2025-01-13 · Teva Pharmaceuticals USA, Inc. · $3,094.00 · Open Payments source 2025-02-04 · Teva Pharmaceuticals USA, Inc. · $7.01 · Open Payments source 2025-03-04 · Teva Pharmaceuticals USA, Inc. · $7.94 · Open Payments source 2025-03-25 · Teva Pharmaceuticals USA, Inc. · $8.88 · Open Payments source 2025-03-30 · Teva Pharmaceuticals USA, Inc. · $6,510.00 · Open Payments source 2025-04-01 · Teva Pharmaceuticals USA, Inc. · $9.70 · Open Payments source 2025-04-10 · Teva Pharmaceuticals USA, Inc. · $7.38 · Open Payments source 2025-04-22 · Teva Pharmaceuticals USA, Inc. · $8.74 · Open Payments source 2025-05-08 · Teva Pharmaceuticals USA, Inc. · $6.68 · Open Payments source 2025-05-27 · Teva Pharmaceuticals USA, Inc. · $8.17 · Open Payments source 2025-06-03 · Teva Pharmaceuticals USA, Inc. · $15.25 · Open Payments source 2025-06-24 · Teva Pharmaceuticals USA, Inc. · $8.20 · Open Payments source 2025-07-01 · Teva Pharmaceuticals USA, Inc. · $27.01 · Open Payments source 2025-07-22 · Teva Pharmaceuticals USA, Inc. · $7.21 · Open Payments source 2025-08-05 · Teva Pharmaceuticals USA, Inc. · $12.92 · Open Payments source 2025-08-25 · Teva Pharmaceuticals USA, Inc. · $460.00 · Open Payments source 2025-09-02 · Teva Pharmaceuticals USA, Inc. · $27.80 · Open Payments source 2025-09-10 · Teva Pharmaceuticals USA, Inc. · $7.16 · Open Payments source 2025-09-24 · Teva Pharmaceuticals USA, Inc. · $975.98 · Open Payments source 2025-09-24 · Teva Pharmaceuticals USA, Inc. · $3,094.00 · Open Payments source 2025-09-30 · Teva Pharmaceuticals USA, Inc. · $14.85 · Open Payments source 2025-10-02 · Teva Pharmaceuticals USA, Inc. · $16.49 · Open Payments source 2025-10-16 · Teva Pharmaceuticals USA, Inc. · $6.12 · Open Payments source 2025-10-22 · Teva Pharmaceuticals USA, Inc. · $6.21 · Open Payments source 2025-10-30 · Teva Pharmaceuticals USA, Inc. · $19.07 · Open Payments source 2025-11-12 · Teva Pharmaceuticals USA, Inc. · $22.97 · Open Payments source 2025-12-02 · Teva Pharmaceuticals USA, Inc. · $7.16 · Open Payments source 2025-12-09 · Teva Pharmaceuticals USA, Inc. · $19.90 · Open Payments source
UZEDY Normalized: uzedy	Drug	Teva Pharmaceuticals USA, Inc.	$12,653.19	18	2025
Source payment records 2025-02-11 · Teva Pharmaceuticals USA, Inc. · $18.74 · Open Payments source 2025-02-13 · Teva Pharmaceuticals USA, Inc. · $139.15 · Open Payments source 2025-03-20 · Teva Pharmaceuticals USA, Inc. · $170.85 · Open Payments source 2025-03-26 · Teva Pharmaceuticals USA, Inc. · $42.70 · Open Payments source 2025-03-26 · Teva Pharmaceuticals USA, Inc. · $7.68 · Open Payments source 2025-03-26 · Teva Pharmaceuticals USA, Inc. · $2,380.00 · Open Payments source 2025-04-16 · Teva Pharmaceuticals USA, Inc. · $20.08 · Open Payments source 2025-05-20 · Teva Pharmaceuticals USA, Inc. · $17.92 · Open Payments source 2025-06-12 · Teva Pharmaceuticals USA, Inc. · $21.74 · Open Payments source 2025-06-18 · Teva Pharmaceuticals USA, Inc. · $1,456.46 · Open Payments source 2025-06-18 · Teva Pharmaceuticals USA, Inc. · $113.40 · Open Payments source 2025-06-18 · Teva Pharmaceuticals USA, Inc. · $3,570.00 · Open Payments source 2025-10-08 · Teva Pharmaceuticals USA, Inc. · $20.02 · Open Payments source 2025-10-19 · Teva Pharmaceuticals USA, Inc. · $420.00 · Open Payments source 2025-11-06 · Teva Pharmaceuticals USA, Inc. · $143.69 · Open Payments source 2025-11-12 · Teva Pharmaceuticals USA, Inc. · $1,013.51 · Open Payments source 2025-11-12 · Teva Pharmaceuticals USA, Inc. · $3.25 · Open Payments source 2025-11-12 · Teva Pharmaceuticals USA, Inc. · $3,094.00 · Open Payments source
VRAYLAR Normalized: vraylar	Drug	ABBVIE INC.	$5,311.66	42	2025
Source payment records 2025-01-07 · ABBVIE INC. · $21.55 · Open Payments source 2025-01-09 · ABBVIE INC. · $7.28 · Open Payments source 2025-01-23 · ABBVIE INC. · $6.80 · Open Payments source 2025-01-27 · ABBVIE INC. · $6.13 · Open Payments source 2025-01-29 · ABBVIE INC. · $115.53 · Open Payments source 2025-01-29 · ABBVIE INC. · $60.20 · Open Payments source 2025-01-30 · ABBVIE INC. · $6.10 · Open Payments source 2025-02-03 · ABBVIE INC. · $7.70 · Open Payments source 2025-02-21 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-03-03 · ABBVIE INC. · $10.00 · Open Payments source 2025-03-03 · ABBVIE INC. · $28.52 · Open Payments source 2025-03-18 · ABBVIE INC. · $13.34 · Open Payments source 2025-03-24 · ABBVIE INC. · $9.55 · Open Payments source 2025-04-01 · ABBVIE INC. · $20.95 · Open Payments source 2025-04-03 · ABBVIE INC. · $108.19 · Open Payments source 2025-04-03 · ABBVIE INC. · $25.20 · Open Payments source 2025-04-17 · ABBVIE INC. · $11.41 · Open Payments source 2025-04-23 · ABBVIE INC. · $8.34 · Open Payments source 2025-04-29 · ABBVIE INC. · $2,250.00 · Open Payments source 2025-05-13 · ABBVIE INC. · $14.83 · Open Payments source 2025-06-09 · ABBVIE INC. · $7.54 · Open Payments source 2025-06-11 · ABBVIE INC. · $27.02 · Open Payments source 2025-06-18 · ABBVIE INC. · $4.64 · Open Payments source 2025-06-25 · ABBVIE INC. · $8.64 · Open Payments source 2025-07-15 · ABBVIE INC. · $15.92 · Open Payments source 2025-07-18 · ABBVIE INC. · $33.85 · Open Payments source 2025-08-06 · ABBVIE INC. · $25.18 · Open Payments source 2025-08-21 · ABBVIE INC. · $11.00 · Open Payments source 2025-08-25 · ABBVIE INC. · $25.48 · Open Payments source 2025-09-11 · ABBVIE INC. · $12.75 · Open Payments source 2025-09-23 · ABBVIE INC. · $12.50 · Open Payments source 2025-09-29 · ABBVIE INC. · $5.46 · Open Payments source 2025-10-07 · ABBVIE INC. · $9.99 · Open Payments source 2025-10-13 · ABBVIE INC. · $8.15 · Open Payments source 2025-10-21 · ABBVIE INC. · $16.75 · Open Payments source 2025-10-22 · ABBVIE INC. · $17.92 · Open Payments source 2025-10-23 · ABBVIE INC. · $4.74 · Open Payments source 2025-11-03 · ABBVIE INC. · $19.90 · Open Payments source 2025-11-10 · ABBVIE INC. · $24.70 · Open Payments source 2025-11-24 · ABBVIE INC. · $10.62 · Open Payments source 2025-12-10 · ABBVIE INC. · $15.62 · Open Payments source 2025-12-24 · ABBVIE INC. · $11.67 · Open Payments source
INGREZZA Normalized: ingrezza	Drug	Neurocrine BioSciences, Inc.	$470.27	13	2025
Source payment records 2025-02-06 · Neurocrine BioSciences, Inc. · $14.50 · Open Payments source 2025-02-14 · Neurocrine BioSciences, Inc. · $125.00 · Open Payments source 2025-02-14 · Neurocrine BioSciences, Inc. · $125.00 · Open Payments source 2025-03-25 · Neurocrine BioSciences, Inc. · $18.35 · Open Payments source 2025-04-08 · Neurocrine BioSciences, Inc. · $21.29 · Open Payments source 2025-04-14 · Neurocrine BioSciences, Inc. · $25.01 · Open Payments source 2025-05-08 · Neurocrine BioSciences, Inc. · $15.14 · Open Payments source 2025-05-21 · Neurocrine BioSciences, Inc. · $21.06 · Open Payments source 2025-08-20 · Neurocrine BioSciences, Inc. · $17.39 · Open Payments source 2025-08-27 · Neurocrine BioSciences, Inc. · $16.53 · Open Payments source 2025-09-02 · Neurocrine BioSciences, Inc. · $30.93 · Open Payments source 2025-09-25 · Neurocrine BioSciences, Inc. · $21.22 · Open Payments source 2025-10-15 · Neurocrine BioSciences, Inc. · $18.85 · Open Payments source
ARISTADA Normalized: aristada	Drug	Alkermes, Inc.	$286.08	15	2025
Source payment records 2025-01-02 · Alkermes, Inc. · $2.97 · Open Payments source 2025-01-02 · Alkermes, Inc. · $13.51 · Open Payments source 2025-01-23 · Alkermes, Inc. · $13.59 · Open Payments source 2025-04-05 · Alkermes, Inc. · $61.69 · Open Payments source 2025-05-07 · Alkermes, Inc. · $17.22 · Open Payments source 2025-05-28 · Alkermes, Inc. · $15.08 · Open Payments source 2025-06-16 · Alkermes, Inc. · $4.98 · Open Payments source 2025-07-03 · Alkermes, Inc. · $26.00 · Open Payments source 2025-07-08 · Alkermes, Inc. · $18.19 · Open Payments source 2025-08-07 · Alkermes, Inc. · $21.94 · Open Payments source 2025-09-04 · Alkermes, Inc. · $19.79 · Open Payments source 2025-11-05 · Alkermes, Inc. · $18.61 · Open Payments source 2025-11-17 · Alkermes, Inc. · $8.87 · Open Payments source 2025-12-15 · Alkermes, Inc. · $17.37 · Open Payments source 2025-12-18 · Alkermes, Inc. · $26.27 · Open Payments source
INVEGA SUSTENNA Normalized: invega sustenna	Drug	Janssen Pharmaceuticals, Inc	$151.92	8	2025
Source payment records 2025-01-13 · Janssen Pharmaceuticals, Inc · $8.42 · Open Payments source 2025-01-29 · Janssen Pharmaceuticals, Inc · $18.22 · Open Payments source 2025-03-12 · Janssen Pharmaceuticals, Inc · $25.58 · Open Payments source 2025-06-09 · Janssen Pharmaceuticals, Inc · $24.87 · Open Payments source 2025-07-10 · Janssen Pharmaceuticals, Inc · $15.95 · Open Payments source 2025-08-21 · Janssen Pharmaceuticals, Inc · $26.70 · Open Payments source 2025-10-01 · Janssen Pharmaceuticals, Inc · $21.45 · Open Payments source 2025-10-27 · Janssen Pharmaceuticals, Inc · $10.73 · Open Payments source
Azstarys Normalized: azstarys	Drug	Corium, LLC	$114.46	7	2025
Source payment records 2025-07-31 · Corium, LLC · $19.96 · Open Payments source 2025-09-11 · Corium, LLC · $18.23 · Open Payments source 2025-10-29 · Corium, LLC · $27.12 · Open Payments source 2025-11-13 · Corium, LLC · $19.66 · Open Payments source 2025-11-19 · Corium, LLC · $5.09 · Open Payments source 2025-12-11 · Corium, LLC · $19.25 · Open Payments source 2025-12-17 · Corium, LLC · $5.15 · Open Payments source
Auvelity Normalized: auvelity	Drug	Axsome Therapeutics, Inc.	$100.33	4	2025
Source payment records 2025-04-29 · Axsome Therapeutics, Inc. · $25.68 · Open Payments source 2025-06-24 · Axsome Therapeutics, Inc. · $14.58 · Open Payments source 2025-10-07 · Axsome Therapeutics, Inc. · $28.80 · Open Payments source 2025-12-02 · Axsome Therapeutics, Inc. · $31.27 · Open Payments source
ARISTADA INITIO Normalized: aristada initio	Drug	Alkermes, Inc.	$84.94	6	2025
Source payment records 2025-01-23 · Alkermes, Inc. · $13.59 · Open Payments source 2025-06-16 · Alkermes, Inc. · $4.98 · Open Payments source 2025-07-08 · Alkermes, Inc. · $18.19 · Open Payments source 2025-08-07 · Alkermes, Inc. · $21.94 · Open Payments source 2025-11-17 · Alkermes, Inc. · $8.87 · Open Payments source 2025-12-15 · Alkermes, Inc. · $17.37 · Open Payments source
Qelbree Normalized: qelbree	Drug	Supernus Pharmaceuticals, Inc.	$79.07	4	2025
Source payment records 2025-03-26 · Supernus Pharmaceuticals, Inc. · $19.42 · Open Payments source 2025-06-30 · Supernus Pharmaceuticals, Inc. · $17.00 · Open Payments source 2025-09-08 · Supernus Pharmaceuticals, Inc. · $21.69 · Open Payments source 2025-10-21 · Supernus Pharmaceuticals, Inc. · $20.96 · Open Payments source
SPRAVATO Normalized: spravato	Drug	Janssen Pharmaceuticals, Inc	$75.00	4	2025
Source payment records 2025-03-05 · Janssen Pharmaceuticals, Inc · $17.93 · Open Payments source 2025-05-05 · Janssen Pharmaceuticals, Inc · $21.58 · Open Payments source 2025-07-07 · Janssen Pharmaceuticals, Inc · $23.04 · Open Payments source 2025-08-18 · Janssen Pharmaceuticals, Inc · $12.45 · Open Payments source
TRINTELLIX Normalized: trintellix	Drug	Takeda Pharmaceuticals U.S.A., Inc.	$65.57	4	2025
Source payment records 2025-02-04 · Takeda Pharmaceuticals U.S.A., Inc. · $15.39 · Open Payments source 2025-05-06 · Takeda Pharmaceuticals U.S.A., Inc. · $14.61 · Open Payments source 2025-09-29 · Takeda Pharmaceuticals U.S.A., Inc. · $19.47 · Open Payments source 2025-10-14 · Takeda Pharmaceuticals U.S.A., Inc. · $16.10 · Open Payments source
ZURZUVAE Normalized: zurzuvae	Drug	Sage Therapeutics, LLC	$64.34	3	2025
Source payment records 2025-07-21 · Sage Therapeutics, LLC · $21.69 · Open Payments source 2025-09-08 · Sage Therapeutics, LLC · $21.69 · Open Payments source 2025-10-21 · Sage Therapeutics, LLC · $20.96 · Open Payments source
Jornay PM Normalized: jornay pm	Drug	Collegium Pharmaceutical, Inc.	$55.41	3	2025
Source payment records 2025-01-08 · Collegium Pharmaceutical, Inc. · $19.18 · Open Payments source 2025-07-23 · Collegium Pharmaceutical, Inc. · $16.79 · Open Payments source 2025-12-22 · Collegium Pharmaceutical, Inc. · $19.44 · Open Payments source
LOREEV XR Normalized: loreev xr	Drug	Almatica Pharma LLC	$46.69	3	2025
Source payment records 2025-04-30 · Almatica Pharma LLC · $14.18 · Open Payments source 2025-09-09 · Almatica Pharma LLC · $14.18 · Open Payments source 2025-11-18 · Almatica Pharma LLC · $18.33 · Open Payments source
HETLIOZ Normalized: hetlioz	Drug	Vanda Pharmaceuticals Inc.	$34.78	2	2025
Source payment records 2025-07-14 · Vanda Pharmaceuticals Inc. · $14.38 · Open Payments source 2025-09-17 · Vanda Pharmaceuticals Inc. · $20.40 · Open Payments source
ABILIFY ASIMTUFII Normalized: abilify asimtufii	Drug	Otsuka America Pharmaceutical, Inc.	$20.78	1	2025
Source payment records 2025-02-18 · Otsuka America Pharmaceutical, Inc. · $20.78 · Open Payments source
ABILIFY MAINTENA Normalized: abilify maintena	Drug	Otsuka America Pharmaceutical, Inc.	$20.78	1	2025
Source payment records 2025-02-18 · Otsuka America Pharmaceutical, Inc. · $20.78 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
AUSTEDO XR austedo xr	2025	Austedo Xr	2024	19 Beneficiary count suppressed	exact normalized	Medicare Part D
Auvelity auvelity	2025	Auvelity	2024	15 Beneficiary count suppressed	exact normalized	Medicare Part D
Azstarys azstarys	2025	Azstarys	2024	12 Beneficiary count suppressed	exact normalized	Medicare Part D
CAPLYTA caplyta	2025	Caplyta	2024	43 Beneficiary count suppressed	exact normalized	Medicare Part D
LYBALVI lybalvi	2025	Lybalvi	2024	56 Beneficiary count suppressed	exact normalized	Medicare Part D
REXULTI rexulti	2025	Rexulti	2024	31 Beneficiary count suppressed	exact normalized	Medicare Part D
TRINTELLIX trintellix	2025	Trintellix	2024	132	exact normalized	Medicare Part D
VRAYLAR vraylar	2025	Vraylar	2024	40	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
ABBVIE INC. Exact reporting entity; no affiliate inference	2025	VRAYLAR open payments reported associated product	CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550	Vraylar · 2024 Exact normalized brand match · 1 Part D row	40	12
Alkermes, Inc. Exact reporting entity; no affiliate inference	2025	LYBALVI open payments reported associated product	CMS Open Payments — General Payments 93784 supporting records · 20135 recipient NPIs · example record 1222428566	Lybalvi · 2024 Exact normalized brand match · 1 Part D row	56	suppressed by CMS
Axsome Therapeutics, Inc. Exact reporting entity; no affiliate inference	2025	Auvelity open payments reported associated product	CMS Open Payments — General Payments 116023 supporting records · 35298 recipient NPIs · example record 1235293064	Auvelity · 2024 Exact normalized brand match · 1 Part D row	15	suppressed by CMS
Corium, LLC Exact reporting entity; no affiliate inference	2025	Azstarys open payments reported associated product	CMS Open Payments — General Payments 54930 supporting records · 15827 recipient NPIs · example record 1185762907	Azstarys · 2024 Exact normalized brand match · 1 Part D row	12	suppressed by CMS
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) Exact reporting entity; no affiliate inference	2025	CAPLYTA open payments reported associated product	CMS Open Payments — General Payments 211855 supporting records · 46143 recipient NPIs · example record 1241243071	Caplyta · 2024 Exact normalized brand match · 1 Part D row	43	suppressed by CMS
Janssen Pharmaceuticals, Inc Exact reporting entity; no affiliate inference	2025	Caplyta open payments reported associated product	CMS Open Payments — General Payments 11 supporting records · 9 recipient NPIs · example record 1174547314	Caplyta · 2024 Exact normalized brand match · 1 Part D row	43	suppressed by CMS
Lundbeck LLC Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986	Rexulti · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	NUEDEXTA open payments reported associated product	CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901	Nuedexta · 2024 Exact normalized brand match · 1 Part D row	39	suppressed by CMS
Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708	Rexulti · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference	2025	REXULTI open payments reported associated product	CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865	Rexulti · 2024 Exact normalized brand match · 1 Part D row	31	suppressed by CMS
Takeda Pharmaceuticals U.S.A., Inc. Exact reporting entity; no affiliate inference	2025	TRINTELLIX open payments reported associated product	CMS Open Payments — General Payments 37075 supporting records · 14402 recipient NPIs · example record 1223616266	Trintellix · 2024 Exact normalized brand match · 1 Part D row	132	21
Teva Pharmaceuticals USA, Inc. Exact reporting entity; no affiliate inference	2025	AUSTEDO XR open payments reported associated product	CMS Open Payments — General Payments 86263 supporting records · 23643 recipient NPIs · example record 1247244228	Austedo Xr · 2024 Exact normalized brand match · 1 Part D row	19	suppressed by CMS

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Alprazolam	Alprazolam	396	74
Sertraline Hcl	Sertraline Hcl	237	34
Clonazepam	Clonazepam	217	40
Quetiapine Fumarate	Quetiapine Fumarate	208	28
Lorazepam	Lorazepam	207	36
Trazodone Hcl	Trazodone Hcl	198	40
Duloxetine Hcl	Duloxetine Hcl	196	25
Fluoxetine Hcl	Fluoxetine Hcl	174	27
Olanzapine	Olanzapine	164	15
Gabapentin	Gabapentin	143	24
Mirtazapine	Mirtazapine	141	25
Escitalopram Oxalate	Escitalopram Oxalate	137	24
Trintellix	Vortioxetine Hydrobromide	132	21
Lithium Carbonate	Lithium Carbonate	117	16
Lamotrigine	Lamotrigine	112	15
Aripiprazole	Aripiprazole	102	23
Venlafaxine Hcl Er	Venlafaxine Hcl	100	14
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	99	20
Bupropion Xl	Bupropion Hcl	90	18
Divalproex Sodium Er	Divalproex Sodium	74	suppressed
Citalopram Hbr	Citalopram Hydrobromide	69	12
Benztropine Mesylate	Benztropine Mesylate	64	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	61	16
Hydroxyzine Hcl	Hydroxyzine Hcl	58	suppressed
Risperidone	Risperidone	58	suppressed
Buspirone Hcl	Buspirone Hcl	57	13
Lybalvi	Olanzapine/Samidorphan Malate	56	suppressed
Quetiapine Fumarate Er	Quetiapine Fumarate	56	12
Dextroamphetamine-Amphet Er	Dextroamphetamine/Amphetamine	50	11
Clozapine	Clozapine	49	suppressed
Lithium Carbonate Er	Lithium Carbonate	48	suppressed
Caplyta	Lumateperone Tosylate	43	suppressed
Diazepam	Diazepam	43	12
Paliperidone Er	Paliperidone	43	suppressed
Hydroxyzine Pamoate	Hydroxyzine Pamoate	40	11
Vraylar	Cariprazine Hcl	40	12
Nuedexta	Dextromethorphan Hbr/Quinidine	39	suppressed
Quviviq	Daridorexant Hcl	39	suppressed
Prazosin Hcl	Prazosin Hcl	37	suppressed
Bupropion Hcl Sr	Bupropion Hcl	35	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	34	suppressed
Doxepin Hcl	Doxepin Hcl	32	suppressed
Rexulti	Brexpiprazole	31	suppressed
Vilazodone Hcl	Vilazodone Hcl	28	suppressed
Eszopiclone	Eszopiclone	27	suppressed
Ropinirole Hcl	Ropinirole Hcl	26	suppressed
Clomipramine Hcl	Clomipramine Hcl	25	suppressed
Amantadine	Amantadine Hcl	23	suppressed
Fluvoxamine Maleate	Fluvoxamine Maleate	23	suppressed
Topiramate	Topiramate	23	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	23	suppressed
Adzenys Xr-Odt	Amphetamine	22	suppressed
Divalproex Sodium	Divalproex Sodium	22	suppressed
Belsomra	Suvorexant	21	suppressed
Desvenlafaxine Succinate Er	Desvenlafaxine Succinate	20	suppressed
Austedo Xr	Deutetrabenazine	19	suppressed
Oxcarbazepine	Oxcarbazepine	19	suppressed
Atomoxetine Hcl	Atomoxetine Hcl	17	suppressed
Haloperidol	Haloperidol	16	suppressed
Temazepam	Temazepam	16	suppressed
Auvelity	Dextromethorphan Hbr/Bupropion	15	suppressed
Chlorpromazine Hcl	Chlorpromazine Hcl	13	suppressed
Methylphenidate Er	Methylphenidate Hcl	13	suppressed
Olanzapine Odt	Olanzapine	13	suppressed
Azstarys	Serdexmethylphen/Dexmethylphen	12	suppressed
Klonopin	Clonazepam	12	suppressed
Nuplazid	Pimavanserin Tartrate	12	suppressed
Paroxetine Hcl	Paroxetine Hcl	12	suppressed
Carbamazepine	Carbamazepine	11	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Oxazepam	Oxazepam	11	suppressed
Perphenazine	Perphenazine	11	suppressed
Tranylcypromine Sulfate	Tranylcypromine Sulfate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$258,179.01 · 464 records	ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.)	ABILIFY ASIMTUFII, ABILIFY MAINTENA, ARISTADA, ARISTADA INITIO, AUSTEDO XR, Auvelity, Azstarys, CAPLYTA, COBENFY, FANAPT, HETLIOZ, INGREZZA, INVEGA SUSTENNA, Jornay PM, LOREEV XR, LYBALVI, Qelbree, REXULTI, SPRAVATO, TRINTELLIX, UZEDY, VRAYLAR, ZURZUVAE	12	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Austedo Xr play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error